OncoMatch/Clinical Trials/NCT06397235
DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC
Is NCT06397235 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including DEB-TACE+HAIC and DEB-TACE for hepatocellular carcinoma non-resectable.
Treatment: DEB-TACE+HAIC · DEB-TACE — This study is conducted to evaluate the efficacy and safety of transarterial chemoembolization with drug-eluting beads (DEB-TACE) combined with hepatic artery infusion chemotherapy (HAIC) with oxaliplatin and raltitrexed (RALOX-HAIC) versus DEB-TACE alone for unresectable large hepatocellular carcinoma (HCC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: palliative treatment (TACE, transcatheter arterial embolization, HAIC, radiation therapy, systemic therapy)
Previous palliative treatments, including TACE, transcatheter arterial embolization, HAIC, radiation therapy, systemic therapy
Lab requirements
Blood counts
platelet count ≥75×10^9/L, leukocyte >3.0×10^9/L, Neutrophil count ≥1.5×10^9/L
Kidney function
creatinine clearance≤1.5×ULN
Liver function
Child-Pugh score 5-7; ASL and AST≤5×ULN; prolongation of prothrombin time ≤4 seconds
Adequate organ and hematologic function with platelet count ≥75×10^9/L, leukocyte >3.0×10^9/L, Neutrophil count ≥1.5×10^9/L, ASL and AST≤5×ULN, creatinine clearance≤1.5×ULN, and prolongation of prothrombin time ≤4 seconds
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify